Physician profile
Michael T Young
NPI 1023174042
$3,773.47
in general payments reported to CMS, 2019-2025
23 companies · $937 in 2025
The $937 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $331 · 2021: $420 · 2022: $460 · 2023: $583 · 2024: $900 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,376 · Travel and Lodging: $43.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.11 |
| Travel and Lodging | $43.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $734.44 | 2022-2025 | Botox, Qulipta |
| Allergan, INC. | $392.22 | 2019-2022 | |
| Indivior INC. | $386.28 | 2019-2025 | Sublocade |
| Abbott Laboratories | $383.72 | 2022-2025 | Eterna, Proclaim |
| Biotronik Nro, INC. | $335.77 | 2025 | Prospera |
| Pfizer INC. | $294.69 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $230.71 | 2023-2025 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $165.96 | 2022 | |
| Biogen, INC. | $163.50 | 2024-2025 | Spinraza |
| Medtronic, INC. | $112.37 | 2022-2025 | Intellis Adaptivestim, Inceptiv, V-Loc 180 |
| Biodelivery Sciences International, INC. | $105.83 | 2019-2021 | |
| Amgen INC. | $89.82 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $63.17 | 2020-2021 | |
| Braeburn INC. | $60.90 | 2023-2025 | Brixadi |
| Relievant Medsystems, INC. | $59.33 | 2020-2023 | Intracept |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $47.12 | 2025 | Qutenza |
| Stryker Corporation | $31.37 | 2021 | |
| Vertos Medical, INC. | $25.68 | 2024 | Mild Device Kit |
| Lilly USA, LLC | $21.95 | 2019 | |
| Boston Scientific Corporation | $21.39 | 2025 | Intracept |
| Teva Pharmaceuticals USA, INC. | $20.19 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $14.51 | 2025 | |
| Supernus Pharmaceuticals, INC. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.